CAR T-cell therapy in India has emerged as a significant advanced treatment option for selected patients with relapsed or refractory blood cancers. Unlike traditional chemotherapy, CAR-T treatment is a personalised cellular therapy in which the patient’s T cells are collected, genetically modified to recognise cancer cells, expanded and reintroduced into the body.<\/p>\n\n\n\n
In India, CAR T-cell therapy is provided at select specialised cancer centres with haematology-oncology, cellular therapy, critical care, infection-control and laboratory services.<\/p>\n\n\n\n
Existing Indian CAR-T treatments primarily target specific B-cell leukaemias and lymphomas. Eligibility for other blood cancers depends on the approved treatment, available programmes and specialist evaluation.<\/p>\n\n\n\n
For international patients exploring advanced medical treatment in India<\/strong><\/a>, choosing an appropriate hospital and experienced specialist is just as important as understanding the treatment itself.<\/p>\n\n\n\n CAR-T, or chimeric antigen receptor T-cell therapy, is a type of personalised immunotherapy.<\/p>\n\n\n\n The patient’s T cells are collected and genetically engineered to recognise a specific target found on cancer cells. After laboratory expansion, the modified cells are infused back into the patient.<\/p>\n\n\n\n Most currently approved Indian CAR-T pathways are CD19-based and used for selected relapsed or refractory B-cell acute lymphoblastic leukaemia and large B-cell lymphoma.<\/p>\n\n\n\n This means CAR T-cell therapy is not a universal alternative to chemotherapy, radiation or stem-cell transplantation. Its suitability depends on the diagnosis, previous treatments, disease status and general health.<\/p>\n\n\n\n For a broader understanding of available treatments, patients can explore blood cancer treatment options in India<\/strong><\/a>.<\/p>\n\n\n\n CAR T therapy eligibility<\/strong> requires specialist evaluation because having blood cancer does not automatically make a patient suitable for the treatment.<\/p>\n\n\n\n Doctors may review:<\/p>\n\n\n\n CD19-targeted CAR-T treatments may be considered for selected adults with relapsed or refractory B-cell acute lymphoblastic leukaemia, depending on the approved product and clinical requirements.<\/p>\n\n\n\n Patients exploring leukaemia treatment in India<\/strong><\/a> should have their pathology reports, flow cytometry results, bone marrow findings and previous treatment history reviewed before assuming CAR-T is appropriate.<\/p>\n\n\n\n CAR-T therapy may also be used for selected relapsed or refractory large B-cell lymphomas.<\/p>\n\n\n\n Patients seeking lymphoma treatment in India may be evaluated for CAR-T when their cancer has returned or has not responded adequately to previous treatment.<\/p>\n\n\n\n The available options depend on lymphoma subtype, previous therapy and the approved CAR-T product.<\/p>\n\n\n\n Patients can also review blood cancer treatment risks and available treatment approaches<\/strong><\/a> to understand why treatment plans differ between blood cancers.<\/p>\n\n\n\n CAR-T therapies targeting certain antigens are used for selected multiple myeloma patients internationally. However, the availability of approved products and eligible treatment programmes in India must be confirmed directly with specialist centres.<\/p>\n\n\n\n The CD19-targeted mechanism used for some leukaemias and lymphomas cannot automatically be applied to multiple myeloma.<\/p>\n\n\n\n The CAR T-cell therapy process<\/strong> involves several carefully controlled stages and generally requires multiple hospital visits.<\/p>\n\n\n\n A haemato-oncology specialist reviews the patient’s diagnosis, pathology results, imaging, treatment history, organ function, infections and general fitness.<\/p>\n\n\n\n A second medical opinion through specialist consultation<\/strong><\/a> can help international patients understand their available treatment options before travelling.<\/p>\n\n\n\n If the patient is eligible, T cells are collected through a procedure called leukapheresis.<\/p>\n\n\n\n A specialised machine separates the required cells from the blood, while the remaining blood components are returned to the patient.<\/p>\n\n\n\n Collected T cells undergo specialised laboratory processing.<\/p>\n\n\n\n The cells are genetically modified to recognise a specific cancer-related target, expanded and tested before infusion.<\/p>\n\n\n\n This manufacturing process is one of the major differences between CAR T-cell treatment and conventional ready-to-use cancer medicines.<\/p>\n\n\n\n Some patients require temporary chemotherapy or another treatment while CAR-T cells are being manufactured.<\/p>\n\n\n\n This helps manage disease activity during the waiting period when clinically necessary.<\/p>\n\n\n\n Before CAR-T infusion, patients usually receive a short course of chemotherapy to prepare the immune system.<\/p>\n\n\n\n This creates a more favourable environment for the infused CAR-T cells.<\/p>\n\n\n\n Patients may therefore undergo chemotherapy as part of their CAR-T treatment pathway.<\/p>\n\n\n\n Once the modified cells are ready, they are infused intravenously.<\/p>\n\n\n\n The medical team then monitors treatment response and possible complications.<\/p>\n\n\n\n Hospitals offering CAR T-cell therapy need qualified haematology and oncology teams, critical care facilities and the ability to promptly identify treatment-related toxicity.<\/p>\n\n\n\n The best hospital depends on the diagnosis, CAR-T product, age, previous treatments and patient eligibility.<\/p>\n\n\n\n The following hospitals are part of Panacea Medcare’s hospital network and have reported advanced haematology, oncology or CAR-T capabilities. Patients should confirm current CAR-T availability and product-specific eligibility directly with each centre.<\/p>\n\n\n\n Apollo Hospitals Jubilee Hills is recognised for advanced cancer care and specialised medical facilities.<\/p>\n\n\n\n Panacea Medcare includes Apollo Hospitals within its network of hospitals in India<\/strong><\/a>.<\/p>\n\n\n\n Patients considering CAR-T treatment should confirm the hospital’s current programme, available products and relevant specialist team.<\/p>\n\n\n\n Fortis Memorial Research Institute is part of Panacea Medcare’s hospital network.<\/p>\n\n\n\n The hospital offers advanced haematology-oncology and bone marrow transplant services, with reported CAR-T capabilities.<\/p>\n\n\n\n Its established transplant infrastructure makes it one of the centres patients may consider when seeking specialised blood cancer treatment.<\/p>\n\n\n\n For related treatment information, explore bone marrow transplant hospitals in India<\/strong><\/a>.<\/p>\n\n\n\n Max Saket offers specialised haematology, bone marrow transplantation and oncology services.<\/p>\n\n\n\n Its advanced facilities and multidisciplinary teams support the management of complex blood cancers.<\/p>\n\n\n\n CAR-T treatment eligibility and availability should be confirmed with its cellular therapy specialists.<\/p>\n\n\n\n Medanta is another hospital within Panacea Medcare’s network.<\/p>\n\n\n\n Its haematology and bone marrow transplant services provide specialist support for patients with complex blood disorders.<\/p>\n\n\n\n The hospital has described CAR-T treatment pathways for selected B-cell malignancies.<\/p>\n\n\n\n International patients should compare available programmes based on diagnosis and required treatment rather than hospital popularity alone.<\/p>\n\n\n\n For a broader comparison, review leading hospitals in India for international patients<\/strong><\/a>.<\/p>\n\n\n\n Patients searching for experienced CAR T-cell therapy specialists should focus on haematologists, haemato-oncologists, cellular therapy specialists and bone marrow transplant physicians.<\/p>\n\n\n\n Experience in treating complex blood cancers is particularly important.<\/p>\n\n\n\n Dr Shishir Seth<\/strong><\/a> is listed by Panacea Medcare as a specialist in leukaemia, lymphoma, myelodysplastic syndromes, stem-cell transplantation and complex blood disorders.<\/p>\n\n\n\n He has experience in senior haemato-oncology and bone marrow transplant roles associated with Apollo Hospitals, Delhi.<\/p>\n\n\n\n Dr Gaurav Kharya<\/strong><\/a> is a paediatric haematology and bone marrow transplant specialist associated with Apollo Hospitals<\/strong><\/a> in Panacea Medcare’s network.<\/p>\n\n\n\n His clinical background includes complex paediatric blood disorders and transplantation.<\/p>\n\n\n\n Dr Meet Kumar<\/strong><\/a> is a haematology and bone marrow transplant specialist associated with Marengo Asia Hospital, Gurugram<\/strong><\/a>.<\/p>\n\n\n\n His experience includes the management of blood disorders and stem-cell transplantation.<\/p>\n\n\n\n These specialists may assist with complex blood cancer assessment. However, being experienced in haematology or BMT does not automatically establish that a doctor personally administers CAR-T therapy.<\/p>\n\n\n\n The treating hospital must confirm the responsible CAR-T specialist and programme.<\/p>\n\n\n\n CAR T-cell therapy side effects<\/strong> can be serious, making specialised monitoring essential.<\/p>\n\n\n\n Two important complications include:<\/p>\n\n\n\n Patients may also develop infections, low blood counts, fatigue or prolonged immune suppression.<\/p>\n\n\n\n CAR T therapy recovery time<\/strong> varies considerably.<\/p>\n\n\n\n Some patients require extended monitoring or additional treatment for complications after infusion.<\/p>\n\n\n\n International patients should avoid booking fixed return flights until their treating specialist confirms that travel is medically appropriate.<\/p>\n\n\n\n Patients comparing CAR-T with other advanced blood cancer treatments can also read about conditions treated through bone marrow transplantation<\/strong><\/a>.<\/p>\n\n\n\n For CAR T-cell therapy for international patients in India<\/strong>, planning should begin before travelling whenever possible.<\/p>\n\n\n\n Patients should provide:<\/p>\n\n\n\n Through international patient coordination, Panacea Medcare can help arrange specialist consultations, hospital selection, medical visa assistance, airport transfers, accommodation and follow-up planning.<\/p>\n\n\n\n Patients planning their journey can refer to the complete guide to medical tourism in India for international patients<\/strong><\/a>.<\/p>\n\n\n\n Those who want to understand specialist evaluation, treatment estimates and travel coordination can also explore advanced medical treatment planning in India<\/strong><\/a>.<\/p>\n\n\n\n This planning is particularly important for CAR-T because treatment involves manufacturing timelines, hospital monitoring and potentially extended recovery.<\/p>\n\n\n\n The cost of CAR T-cell therapy in India<\/strong> using certain indigenous treatment pathways is often estimated at approximately \u20b930\u201340 lakh or more.<\/p>\n\n\n\n However, the total cost varies depending on the CAR-T product, manufacturing, investigations, hospitalisation, complication management and follow-up.<\/p>\n\n\n\n For a detailed financial breakdown, refer to Panacea Medcare’s CAR T-cell therapy cost in India 2026-27 guide<\/a><\/p>\n\n\n\n .<\/p>\n\n\n\n Families comparing treatment expenses across different blood cancers can also explore blood cancer treatment cost in India<\/strong><\/a>.<\/p>\n\n\n\n These figures are indicative and should not be treated as fixed hospital quotations.<\/p>\n\n\n\n Panacea Medcare is a medical tourism<\/strong><\/a> facilitator helping international patients coordinate advanced medical treatment in India.<\/p>\n\n\n\n For CAR T-cell therapy, the team can assist with:<\/p>\n\n\n\nWhat Is CAR T-Cell Therapy?<\/h2>\n\n\n\n
Who May Be Eligible for CAR T-Cell Therapy in India?<\/h2>\n\n\n\n
\n
CAR T Therapy for Leukaemia in India<\/h3>\n\n\n\n
CAR T Therapy for Lymphoma in India<\/h3>\n\n\n\n
What About Multiple Myeloma?<\/h3>\n\n\n\n
CAR T-Cell Therapy Process in India<\/h2>\n\n\n\n
1. Specialist Evaluation<\/h3>\n\n\n\n
2. T-Cell Collection<\/h3>\n\n\n\n
3. CAR-T Cell Manufacturing<\/h3>\n\n\n\n
4. Bridging Treatment if Needed<\/h3>\n\n\n\n
5. Lymphodepleting Chemotherapy<\/h3>\n\n\n\n
6. CAR-T Infusion and Monitoring<\/h3>\n\n\n\n
Best Hospitals for CAR T-Cell Therapy in India<\/h2>\n\n\n\n
Apollo Hospitals Jubilee Hills, Hyderabad<\/h3>\n\n\n\n
Fortis Memorial Research Institute, Gurugram<\/h3>\n\n\n\n
Max Super Speciality Hospital, Saket<\/h3>\n\n\n\n
Medanta \u2013 The Medicity, Gurugram<\/h3>\n\n\n\n
Top Doctors for CAR-T Therapy in India at Panacea Medcare<\/h2>\n\n\n\n
Dr. Shishir Seth<\/h3>\n\n\n\n
Dr. Gaurav Kharya<\/h3>\n\n\n\n
Dr. Meet Kumar<\/h3>\n\n\n\n
Side Effects and Recovery After CAR-T Therapy<\/h2>\n\n\n\n
\n
CAR T-Cell Therapy for International Patients in India<\/h2>\n\n\n\n
\n
What About CAR T-Cell Therapy Cost in India?<\/h2>\n\n\n\n
Why Choose Panacea Medcare for CAR T Treatment in India?<\/h2>\n\n\n\n
\n